智通财经网·2025-12-08 03:45Core Viewpoint - Kailaiying's subsidiary, Kailaiying Biotech, has officially launched its commercial production base in Shanghai Fengxian, marking a significant upgrade in the biopharmaceutical CDMO sector [1] Group 1: Company Developments - Kailaiying's stock rose nearly 3%, currently trading at 79.65 HKD with a transaction volume of 15.5175 million HKD [1] - The Fengxian base is the third major commercial production facility following the Jinshan base and Zhangjiang Science and Technology Center, aimed at accelerating clients' commercial production [1] Group 2: Facility Specifications - The Fengxian base has a planned total construction area of over 130,000 square meters, focusing on ADCs and other biopharmaceuticals [1] - The antibody commercial production capacity (Phase I A) utilizes advanced automation systems and production equipment, featuring 200L/500L/2000L single-use bioreactor production lines and a 20㎡ freeze-dryer [1] - The NDCs commercial production capacity (Phase I B) is expected to commence in January 2026, equipped with 100L-200L-500L conjugation reactors and multiple freeze-dryers [1]